Genetic Variations in ABCG2 Gene Predict Breast Carcinoma Susceptibility and Clinical Outcomes after Treatment with Anthracycline-Based Chemotherapy
Table 2
Correlations of ABCG2 polymorphisms with clinicopathological parameters in patients with breast carcinoma.
Characteristic
ABCG2 G34A
ABCG2 C421A
GG Number(%)
GA/AA Number (%)
†,‡
Adjusted OR (95% CI)
CC Number (%)
CA/AA Number (%)
†,‡
Adjusted OR (95% CI)
Age, yrs
50
268 (46.94)
303 (53.06)
0.760†
1 (reference)
272 (47.64)
299 (52.36)
0.086†
1 (reference)
50
286 (47.83)
312 (52.17)
0.445‡
1.155 (0.798–1.670)
256 (42.81)
342 (57.19)
0.079‡
1.396 (0.963–2.023)
Menopausal status
Premenopausal
263 (45.90)
310 (54.10)
0.316†
1 (reference)
265 (46.25)
308 (53.75)
0.431†
1 (reference)
Postmenopausal
291 (48.83)
305 (51.17)
0.222‡
0.795 (0.549–1.149)
263 (44.13)
333 (55.87)
0.376‡
0.845 (0.583–1.226)
First-degree family history of breast cancer
No
434 (46.8)
493 (53.2)
0.442†
1 (reference)
417 (45.0)
51.0 (55.0)
0.718†
1 (reference)
Yes
120 (49.6)
122 (50.4)
0.414‡
0.888 (0.669–1.180)
112 (46.3)
130 (53.7)
0.713‡
0.948 (0.713–1.260)
Tumor size (cm)
2.0
197 (45.8)
233 (54.2)
0.410†
1 (reference)
192 (44.7)
238 (55.3)
0.753†
1 (reference)
2.0
357 (48.3)
382 (51.7)
0.443‡
0.911 (0.717–1.157)
337 (45.6)
402 (54.4)
0.712‡
0.956 (0.752–1.215)
Histology
IDC
431 (46.1)
503 (53.9)
0.234†
1 (reference)
415 (44.4)
519 (55.6)
0.452†
1 (reference)
ILC
36 (52.9)
32 (47.1)
0.286‡
0.765 (0.467–1.253)
31 (45.6)
37 (54.4)
0.831‡
0.948 (0.577–1.555)
Clinical stages
I or II
290 (43.3)
380 (56.7)
0.001†
1 (reference)
291 (43.4)
379 (56.6)
0.148†
1 (reference)
III or IV
264 (52.9)
235 (47.1)
0.002‡
0.687 (0.543–0.868)
238 (47.7)
261 (52.3)
0.149‡
0.842 (0.666–1.064)
Lymph node metastasis status
Node-negative
291 (46.0)
341 (54.0)
0.317†
1 (reference)
283 (44.8)
349 (55.2)
0.724†
1 (reference)
Node-positive
263 (49.0)
274 (51.0)
0.363‡
0.898 (0.711–1.133)
246 (45.8)
291 (54.2)
0.593‡
0.938 (0.743–1.185)
ER status
Negative
172 (45.1)
209 (54.9)
0.466†
1 (reference)
150 (39.4)
231 (60.6)
0.013†
1 (reference)
Positive
296 (47.5)
327 (52.5)
0.518‡
0.919 (0.710–1.188)
295 (47.4)
328 (52.6)
0.020‡
0.735 (0.566–0.953)
PR status
Negative
190 (47.5)
210 (52.5)
0.699†
1 (reference)
155 (38.8)
245 (61.2)
0.003†
1 (reference)
Positive
278 (46.3)
323 (53.7)
0.663‡
1.058 (0.820–1.367)
290 (48.3)
311 (51.7)
0.004‡
0.687 (0.530–0.8902)
HER2 status
Negative
233 (46.6)
267 (53.4)
0.945†
1 (reference)
222 (44.4)
278 (55.6)
0.828†
1 (reference)
Positive
228 (46.8)
259 (53.2)
0.944‡
0.991 (0.771–1.273)
216 (44.4)
271 (55.6)
0.999‡
1.000 (0.777–1.286)
p53 status
Negative
158 (46.7)
180 (53.3)
0.828†
1 (reference)
142 (42.0)
196 (58.0)
0.155†
1 (reference)
Positive
235 (46.0)
276 (54.0)
0.835‡
1.030 (0.782–1.357)
240 (47.0)
271 (53.0)
0.147‡
0.814 (0.617–1.075)
BRCA1 status
Negative
65 (48.9)
68 (51.1)
0.645†
1 (reference)
55 (41.4)
78 (58.6)
0.626†
1 (reference)
Positive
280 (46.7)
320 (53.3)
0.648‡
1.092 (0.749–1.590)
262 (43.7)
338 (56.3)
0.590‡
0.900 (0.614–1.319)
BRCA2 status
Negative
141 (49.5)
144 (50.5)
0.354†
1 (reference)
118 (41.4)
167 (58.6)
0.406†
1 (reference)
Positive
198 (45.9)
233 (54.1)
0.345‡
1.156 (0.856–1.560)
192 (44.5)
239 (55.5)
0.443‡
0.888 (0.665–1.203)
IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor; p53, tumor suppressor protein 53; BRCA1, breast carcinoma type 1 susceptibility protein; BRCA2, breast carcinoma type 2 susceptibility protein. † values were calculated from 2-sided chi-square tests or Fisher’s exact test. ‡ values were calculated by unconditional logistic regression adjusted for age and menopause state. Adjusted OR and 95% CI values were calculated by unconditional logistic regression adjusted for age and menopause status.
